CPCs represent a compelling and commercially viable therapy.

Although inherited retinal diseases are rare, they collectively represent a large unmet medical need. Age-related macular degeneration, our ultimate target of therapy, is not rare.

CPC treatment has the potential to generate $1.8B in revenue.

Commercialization for the treatment of IRD (year 4) will reach the potential to generate revenues of >$10M/yr.

These calculations do not include previously diagnosed patients with AMD or IRD.

CPCs also have numerous advantages and are compatible with many products already in development.

Interested in learning about opportunities to Invest in the OkuloVision mission? We’d love to hear from you.